FDA warned Pure Arylcyclohexylamine Store it sells unapproved, misbranded ketamine drugs, including an injectable, to U.S. consumers online.
What happened
FDA reviewed the website www.arylcyclohexylamine.com on February 27, 2026 (Establishment Identifier 3043543962) rather than conducting an inspection. The review found ketamine products offered for sale with drug claims, including "KETAMINE 100ML (50MG/ML)" and "KETAMINE TROCHES," with no FDA-approved application for either. FDA said such unapproved products may be contaminated, counterfeit, or contain different amounts or kinds of ingredients than labeled.
What FDA found
The company sells ketamine products that FDA has never approved, which is illegal without an approved application.
Sections 505(a) and 301(d) of the FD&C Act (21 U.S.C. 355(a), 331(d))The labeling does not give adequate directions for use, which makes the drugs misbranded (labeled in a way the law forbids).
Section 502(f)(1) of the FD&C Act (21 U.S.C. 352(f)(1)); 21 CFR 201.5These are prescription drugs that are not safe for a layperson to use without a licensed practitioner, and they do not qualify for the exemption from adequate-directions labeling.
Section 503(b)(1) of the FD&C Act (21 U.S.C. 353(b)(1)); 21 CFR 201.115(a)Website statements, such as calling ketamine "a powerful psychoactive drug," show the products are intended for human use as drugs.
21 CFR 201.128; section 201(g) of the FD&C Act
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must send a written response within 15 business days of receiving the letter to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov, with the corrective steps taken, how it will prevent repeat violations, and supporting documents, citing reference number MARCS-CMS 725151.
Who should pay attention
- online sellers of ketamine and other prescription-only substances
- ketamine clinics and telehealth prescribers that source drugs from unapproved suppliers
- compounding pharmacies and contract manufacturers making ketamine troches or injectables
This is a summary. Read the original letter on fda.gov.